MONTRÉAL, Feb. 23, 2021 (GLOBE NEWSWIRE) — Premier Health of America Inc. (TSXV: PHA) (the “Corporation”), a leading Canadian Healthtech company, announces it has filed its Condensed Interim Consolidated Financial Statements and MD&A for its first quarter ended December 31, 2020.
Summary
“The first quarter of 2021 has set the pace for the reminder of FY2021.” Said Martin Legault, CEO of Premier Health. “Premier Health’s results for this quarter are above our budget and we are continuing on our growth path.”
First Quarter 2021 Results Highlights
December 31, 2020 (3 months) |
December 31, 2019 (3 months) |
|||||
Revenues | $13,360,309 | $3,364,158 | ||||
From last period | +297 | % | ||||
Gross margin | $3,803,468 | $884,605 | ||||
From last period | +330 | % | ||||
EBITDA (1) | $1,318,718 | $215,545 | ||||
From last period | +512 | % | ||||
Net Income | $715,645 | $136,493 | ||||
From last period | +424 | % |
(1) Adjusted EBITDA before non-recurring items
Business Highlights
Financing Highlights
Completion of Code Bleu Acquisition
Premier Health completed the previously announced Code Bleu acquisition on November 6 for a total consideration of C$17 million. The acquisition was financed by a $10M term loan, the issuance of 6,521,740 common shares of the Corporation at $0.69 per share and a $2.5M balance of sale subject to performance objectives. Code Bleu’s Q1-2021 partial consolidation (55 days over a 92 day quarter) added over 87,000 billed hours and revenues of $5.3M to Premier Health’s results.
About Premier Health
Premier Health is a leading Canadian Healthtech company that provides a comprehensive range of staffing and outsourced services solutions for healthcare needs to governments, corporations, and individuals. Premier Health uses its proprietary PSweb platform to lead the healthcare services sector digital transformation to provide patients with faster, cheaper and more accessible care services.
Non-GAAP Measures
Earnings before interest, taxes, depreciation and amortization (“EBITDA”), is calculated as the net profit (loss), before non-recurring items such as acquisition and transaction costs, non-cash expenses (including loss from disposal of assets, impairments, amortization and depreciation), interest expense, net of interest income and income tax expense.
For Further Information Please Contact:
Mr. Jean-Robert Pronovost
Vice-President, Corporate Development
Premier Health of America Inc.
jrpronovost@premierhealth.ca / 1 800 231 9916
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:
This press release contains forward-looking information based on current expectations. Statements about the date of trading of the Corporation’s common shares on the Exchange and final regulatory approvals, among others, are forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. The Corporation assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. These factors and others are more fully discussed in the filings of the Corporation with Canadian securities regulatory authorities available at www.sedar.com.
NEWTOWN, Pa., Dec. 22, 2024 /PRNewswire/ -- The law firm of Edelson Lechtzin LLP is…
Miami, Florida--(Newsfile Corp. - December 21, 2024) - Amid the vibrant backdrop of Art Basel…
Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…
MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…
TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…
Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…